Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Operating Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Operating Expenses data on record, last reported at $17.8 million in Q1 2026.

  • On a quarterly basis, Operating Expenses rose 22.22% to $17.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $55.2 million, a 43.78% increase, with the full-year FY2025 number at $52.0 million, up 81.8% from a year prior.
  • Operating Expenses reached $17.8 million in Q1 2026 per IKT's latest filing, up from $13.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for IKT hit a ceiling of $17.8 million in Q1 2026 and a floor of $4.4 million in Q4 2022.
  • A 5-year average of $8.1 million and a median of $5.1 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: dropped 20.07% in 2024, then skyrocketed 205.25% in 2025.
  • Tracing IKT's Operating Expenses over 5 years: stood at $4.4 million in 2022, then rose by 0.11% to $4.4 million in 2023, then soared by 193.6% to $12.9 million in 2024, then increased by 6.55% to $13.8 million in 2025, then rose by 29.52% to $17.8 million in 2026.
  • Business Quant data shows Operating Expenses for IKT at $17.8 million in Q1 2026, $13.8 million in Q4 2025, and $12.8 million in Q3 2025.